Publications by authors named "Y Hisamatsu"
Article Synopsis
- * The study identified a protein called SHARPIN, located on an amplified chromosome in CRC, which is overexpressed in tumor cells and linked to poor patient prognosis due to its influence on lymphatic invasion.
- * SHARPIN affects the progression of CRC by regulating the proteins MDM2 and p53, leading to changes in cell cycle and apoptosis, thus presenting SHARPIN as a potential new target for therapeutic interventions in colorectal cancer.
Mucoepidermoid carcinoma is the most prevalent malignancy in the salivary gland and is sporadic in the breast. Here, we report a case of breast mucoepidermoid carcinoma with a rare CREB-regulated transcription coactivator 3-mastermind-like transcriptional coactivator 2 () fusion. A 23-year-old female was admitted to our hospital with a left breast palpable mass.
View Article and Find Full Text PDFArticle Synopsis
- The management of colorectal liver metastases (CRLMs) requires a team approach, with debates over the use of angiogenesis inhibitors for RAS mutant tumors.
- A case study of a 37-year-old woman with RAS mutant transverse colon cancer showed long-term disease-free survival through multiple surgeries and the combination treatment of aflibercept and FOLFIRI.
- The findings suggest that a multidisciplinary strategy focused on complete tumor resection, along with the use of aflibercept, can successfully manage recurrent CRLMs and offer extended survival rates.
Apoptosis is programmed cell death that eliminates undesired cells to maintain homeostasis in metazoan. Aberration of this process may lead to cancer genesis. The tumor necrosis factor related apoptosis inducing ligand (TRAIL) induces apoptosis in cancer cells after ligation with death receptors (DR4/DR5) while sparing most normal cells.
View Article and Find Full Text PDFBackground: Concurrent chemoradiotherapy is the standard therapy for locally advanced non-small cell lung cancer (NSCLC). However, there is little evidence supporting its use in older adults. Low-dose daily carboplatin combined with thoracic radiotherapy is considered a standard regimen for this population.
View Article and Find Full Text PDF